Asunto(s)
Cistoadenoma Papilar , Mesotelioma , Epiplón , Proteína Supresora de Tumores del Síndrome de Von Hippel-Lindau , Humanos , Femenino , Cistoadenoma Papilar/patología , Cistoadenoma Papilar/genética , Cistoadenoma Papilar/diagnóstico , Cistoadenoma Papilar/cirugía , Proteína Supresora de Tumores del Síndrome de Von Hippel-Lindau/genética , Mesotelioma/patología , Mesotelioma/genética , Epiplón/patología , Epiplón/cirugía , Mutación , Neoplasias Peritoneales/patología , Neoplasias Peritoneales/genética , Neoplasias Peritoneales/química , Biomarcadores de Tumor/análisis , Biomarcadores de Tumor/genética , Neoplasias de las Trompas Uterinas/patología , Neoplasias de las Trompas Uterinas/genética , Neoplasias de las Trompas Uterinas/química , Inmunofenotipificación , Diagnóstico Diferencial , Persona de Mediana Edad , InmunohistoquímicaRESUMEN
Clear cell papillary cystadenoma of the epididymis is an uncommon benign neoplasm, usually seen in patients with von Hippel-Lindau disease. Morphologic and immunohistochemical examination aid in distinguishing clear cell papillary cystadenoma from malignant histologic mimics including low-grade mesothelial proliferations and metastatic clear cell renal cell carcinomas. Analogous lesions have been described in the female genital tract, often posing diagnostic challenges due to their low incidence. Here, we present the difficult diagnostic aspects of the first case of clear cell papillary cystadenoma involving the ovary, including the salient immunohistochemical, ultrastructural, and molecular characteristics.
Asunto(s)
Carcinoma de Células Renales/diagnóstico por imagen , Cistoadenoma Papilar/diagnóstico por imagen , Neoplasias Ováricas/diagnóstico por imagen , Carcinoma de Células Renales/patología , Cistoadenoma Papilar/genética , Cistoadenoma Papilar/patología , Diagnóstico Diferencial , Femenino , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Inmunohistoquímica , Microscopía Electrónica , Persona de Mediana Edad , Neoplasias Ováricas/patología , Ovario/diagnóstico por imagen , Ovario/patología , Mutación Puntual , Análisis de Secuencia de ADN , Proteína Supresora de Tumores del Síndrome de Von Hippel-Lindau/genéticaAsunto(s)
Cistoadenoma Papilar/diagnóstico , Enfermedades de los Genitales Masculinos/diagnóstico , Escroto/patología , Enfermedad de von Hippel-Lindau/diagnóstico , Adulto , Cistoadenoma Papilar/genética , Cistoadenoma Papilar/patología , Cistoadenoma Papilar/cirugía , Enfermedades de los Genitales Masculinos/genética , Enfermedades de los Genitales Masculinos/patología , Enfermedades de los Genitales Masculinos/cirugía , Humanos , Masculino , Escroto/cirugía , Ultrasonografía , Enfermedad de von Hippel-Lindau/genética , Enfermedad de von Hippel-Lindau/patología , Enfermedad de von Hippel-Lindau/cirugíaRESUMEN
We describe the case of an oncocytic papillary cystadenoma with mucinous differentiation of the parotid gland in a 64-year-old male. Histologically, the tumor exhibited distinctive areas of intracystic papillary growth pattern with microcystic and macrocystic spaces containing mucinous secretions and small crystals. The cyst wall and papillary fronds were lined by oncocytic admixed with numerous mucocytes. Lymphoid tissue and invasive features were not identified. The tumor showed strong expression of CK7 and mammaglobin in oncocytes, and BRST-2 and MUC4 in mucocytes. p63, ER, PR, SOX10, DOG-1, and S100 stains were negative. No rearrangement of the MAML2 gene region or ETV6-NTRK3 fusion transcript was detected. The diagnosis of oncocytic papillary tumor with prominent mucinous differentiation is particularly problematic owing to the large number of potential mimics and should prompt consideration of appropriate molecular studies.
Asunto(s)
Diferenciación Celular , Cistoadenoma Papilar/patología , Neoplasias Quísticas, Mucinosas y Serosas/patología , Células Oxífilas/patología , Neoplasias de la Parótida/patología , Biomarcadores de Tumor/análisis , Biomarcadores de Tumor/genética , Biopsia , Cistoadenoma Papilar/química , Cistoadenoma Papilar/genética , Cistoadenoma Papilar/cirugía , Diagnóstico Diferencial , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Neoplasias Quísticas, Mucinosas y Serosas/química , Neoplasias Quísticas, Mucinosas y Serosas/genética , Neoplasias Quísticas, Mucinosas y Serosas/cirugía , Células Oxífilas/química , Neoplasias de la Parótida/química , Neoplasias de la Parótida/genética , Neoplasias de la Parótida/cirugía , Valor Predictivo de las PruebasRESUMEN
AIMS: Clear cell papillary cystadenoma (CCPC) is associated with von Hippel-Lindau disease (VHLD), but rarely involves mesosalpinx and broad ligament (M/BL). This study provides new data about its behaviour and immunophenotype. METHODS AND RESULTS: We performed an analysis of four benign cases of CCPC of M/BL with either characteristic clinical features or genetic markers [loss of heterozygosity (LOH)] of VHLD in patients ranging from 24 to 36 years and a sporadic case in a 52-year-old presenting with peritoneal metastases. All CCPCs were papillary but had solid and tubular areas. Haemorrhage, thrombosis and scarring were constant features and related to an unusual pattern of sub-epithelial vascularity. All clear or oxyphilic cells co-expressed cytokeratin 7 (CK7), CAM5.2 and vimentin, with strong apical CD10 and nuclear paired box gene 2 (PAX2) immunoreactivity. Three cases also showed positivity for VHL40, epithelial membrane antigen (EMA), Wilms' tumour suppressor gene (WT-1) and cancer antigen 125 (CA125) but only one expressed renal cell carcinoma (RCC) antigen. Vascular plexus overexpressed nuclear and cytoplasmic WT-1. CONCLUSION: The VHLD-associated cases appeared to be benign, but the sporadic case exhibited a low malignant potential. CCPCs show histological and immunophenotypical similarities with the recently reported clear cell papillary RCC, although the previously unreported apical CD10 and nuclear PAX2 expression may be related to their mesonephric origin. CCPC has a distinctive sub-epithelial vascular pattern that is consistent with its pathogenesis.
Asunto(s)
Ligamento Ancho/patología , Cistoadenoma Papilar/patología , Neoplasias de las Trompas Uterinas/patología , Trompas Uterinas/patología , Neoplasias Uterinas/patología , Enfermedad de von Hippel-Lindau/patología , Adulto , Biomarcadores de Tumor/metabolismo , Ligamento Ancho/metabolismo , Cistoadenoma Papilar/complicaciones , Cistoadenoma Papilar/genética , Cistoadenoma Papilar/metabolismo , Neoplasias de las Trompas Uterinas/complicaciones , Neoplasias de las Trompas Uterinas/genética , Neoplasias de las Trompas Uterinas/metabolismo , Trompas Uterinas/metabolismo , Femenino , Humanos , Pérdida de Heterocigocidad , Persona de Mediana Edad , Neoplasias Primarias Múltiples , Neoplasias Uterinas/genética , Neoplasias Uterinas/metabolismo , Proteína Supresora de Tumores del Síndrome de Von Hippel-Lindau/genética , Adulto Joven , Enfermedad de von Hippel-Lindau/complicaciones , Enfermedad de von Hippel-Lindau/genética , Enfermedad de von Hippel-Lindau/metabolismoRESUMEN
Papillary cystadenoma is a rare benign neoplasm of the epididymis, occurring mainly in young adult males. More than one-third of the cases reported in the literature have occurred in patients with von Hippel-Lindau disease. Conversely, epididymal nodules presumed to be papillary cystadenomas are found in one-third of males with von Hippel-Lindau disease. The association is stronger for bilateral tumors. The pathogenesis involves loss of the von Hippel-Lindau gene resulting in overexpression of the angiogenic protein "hypoxia-inducible factor." Papillary cystadenoma is of mesonephric derivation. It originates in the efferent ductules of the head of the epididymis in the form of tiny precursor lesions. Histologically, papillary cystadenoma is characterized by cystic spaces with intracystic papillary projections lined by clear cells, with a resultant resemblance to renal cell carcinoma. Immunohistochemical markers may facilitate the distinction between the 2 tumors. Treatment consists of surgical excision and the prognosis is excellent.
Asunto(s)
Cistoadenoma Papilar/patología , Epidídimo , Neoplasias Testiculares/patología , Adolescente , Adulto , Anciano , Carcinoma de Células Renales/diagnóstico , Carcinoma de Células Renales/secundario , Cistoadenoma Papilar/diagnóstico , Cistoadenoma Papilar/etiología , Cistoadenoma Papilar/genética , Diagnóstico Diferencial , Humanos , Masculino , Persona de Mediana Edad , Neoplasias Testiculares/diagnóstico , Neoplasias Testiculares/etiología , Neoplasias Testiculares/genética , Adulto Joven , Enfermedad de von Hippel-Lindau/diagnóstico , Enfermedad de von Hippel-Lindau/genética , Enfermedad de von Hippel-Lindau/patologíaRESUMEN
We report a rare case of a woman with bilateral papillary cystadenomata of the broad ligament with von Hippel-Lindau disease (VHL) (other manifestations: capillary hemangioblastomas of the spinal cord). Patient surveillance is important, because in the course of VHL-associated tumors malignant lesions may arise that are relevant for the prognosis.
Asunto(s)
Cistoadenoma Papilar/etiología , Neoplasias de las Trompas Uterinas/etiología , Hemangioblastoma/etiología , Neoplasias de la Médula Espinal/etiología , Enfermedad de von Hippel-Lindau/complicaciones , Enfermedad de von Hippel-Lindau/diagnóstico , Cistoadenoma Papilar/genética , Cistoadenoma Papilar/patología , Neoplasias de las Trompas Uterinas/genética , Neoplasias de las Trompas Uterinas/patología , Femenino , Humanos , Mutación Puntual , Vértebras Torácicas , Proteína Supresora de Tumores del Síndrome de Von Hippel-Lindau/genética , Adulto Joven , Enfermedad de von Hippel-Lindau/genéticaRESUMEN
OBJECTIVE: Epidemiologic data suggest that aberrant androgen homeostasis may promote aggressive epithelial ovarian cancer biology. Hyperandrogenism results from both obesity and expression of polymorphic androgen receptor (AR) allelotypes harboring short cytosine-adenine-guanine (CAG) repeat sequences; both have been shown to independently correlate with poor overall survival in ovarian cancer. We have hypothesized that the combination of these factors further manifests an aggressive ovarian cancer phenotype. METHODS: Genotype analysis of the AR CAG polymorphism was performed on 81 patients with papillary serous epithelial ovarian cancer. Medical records were reviewed for body mass index (BMI), clinico-pathologic factors, and survival. Data were examined using the Fishers exact test, Kaplan-Meier survival, and Cox regression analyses. RESULTS: Overweight or obese women (BMI > or = 25) with a short AR allele (< or = 19 CAG repeats) demonstrated statistically shorter progression-free survival (9 months) when compared to underweight or ideal body weight women (BMI < 25) and a long AR allele (> 19 CAG repeats; 26 months, p=0.0002). Overweight/obese women with a short AR allele also demonstrated shorter overall survival (34 months) when compared to underweight/ideal body weight women with a long AR allele (59 months, p=0.036). On multivariate analyses, the combination of a short AR allele and BMI > 25 was an independent poor prognostic factor after controlling for age, stage, grade, optimal cytoreduction, and AR allele length and BMI independently (p=0.05). CONCLUSION: These data provide further evidence that suggest that hyperandrogenism promotes an aggressive epithelial ovarian cancer phenotype.
Asunto(s)
Hiperandrogenismo/genética , Obesidad/genética , Neoplasias Ováricas/genética , Receptores Androgénicos/genética , Alelos , Estudios de Cohortes , Cistoadenoma Papilar/complicaciones , Cistoadenoma Papilar/genética , Cistoadenoma Papilar/patología , Cistadenoma Seroso/complicaciones , Cistadenoma Seroso/genética , Cistadenoma Seroso/patología , Femenino , Genotipo , Humanos , Hiperandrogenismo/complicaciones , Hiperandrogenismo/patología , Persona de Mediana Edad , Estadificación de Neoplasias , Obesidad/complicaciones , Obesidad/patología , Neoplasias Ováricas/complicaciones , Neoplasias Ováricas/patología , Polimorfismo Genético , Repeticiones de TrinucleótidosRESUMEN
von Hippel-Lindau disease is an autosomal dominant inherited disorder characterized by a predisposition to multiple neoplasms. Renal cell carcinoma and hemangioblastomas of the retina and cerebellum are the most common of these, but other neoplasms and cysts also occur throughout the body. We report a distinctive, yet never described lung lesion in a 43-year-old woman with von Hippel-Lindau disease. Molecular genetic studies confirmed the presence of a VHL gene mutation in the cells of this lesion. We discuss the salient features of this novel lesion, and hypothesize on its origin and nature.
Asunto(s)
Cistoadenoma Papilar/patología , Quistes/patología , Neoplasias Pulmonares/patología , Enfermedad de von Hippel-Lindau/patología , Adulto , Biomarcadores de Tumor/análisis , Cistoadenoma Papilar/química , Cistoadenoma Papilar/genética , Cistoadenoma Papilar/cirugía , Quistes/genética , Análisis Mutacional de ADN , Femenino , Eliminación de Gen , Humanos , Neoplasias Pulmonares/química , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/cirugía , Radiografía Torácica , Tomografía Computarizada por Rayos X , Proteína Supresora de Tumores del Síndrome de Von Hippel-Lindau/genética , Enfermedad de von Hippel-Lindau/genéticaRESUMEN
Solid pseudopapillary tumor of pancreas (SPT) is a rare neoplasm that occurs most often in young females with the two distinct features, the 'solid-cystic' gross appearance, and the 'solid-pseudopapillary' microscopic pattern. It has been reported that almost all SPT tumors contain a mutation in the beta-catenin gene; however, the histogenetic origin of this tumor remains largely a mystery. E-cadherin is a cell adhesion molecule that links to catenins to form cell adhesion junctions, which is associated with the cytoskeleton formation. In this study, we examined the expression of E-cadherin and beta-catenin from SPT in an attempt to determine the molecular basis for the unusual morphology of this tumor. Nine cases of SPT were retrieved from Surgical Pathologic Archives of three institutions, including one male and eight females. H&E slides of each case were reviewed to confirm the diagnosis. The beta-catenin gene was sequenced in one case. E-cadherin and beta-catenin immunostains, were performed on all nine cases. Sequencing analysis on one case showed a point mutation of the beta-catenin gene, confirming previous findings that almost all SPT tumors contain mutation in the beta-catenin gene. Immunostains showed that, in both solid and pseudopapillary areas, all the tumor cells lost expression of E-cadherin, and beta-catenin nuclear expression was observed in all cases. Our findings suggest that loss of cytoplasmic beta-catenin protein in the cell adhesion complex due to beta-catenin gene mutation, results in instability of the complex, loss of E-cadherin in cell membrane, and eventually dissociation of the tumor cells to form the pseudopapillary pattern.
Asunto(s)
Moléculas de Adhesión Celular/metabolismo , Cistoadenoma Papilar/metabolismo , Neoplasias Pancreáticas/metabolismo , Adulto , Cadherinas/genética , Cadherinas/metabolismo , Moléculas de Adhesión Celular/genética , Niño , Cistoadenoma Papilar/genética , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Mutación , Neoplasias Pancreáticas/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , beta Catenina/genética , beta Catenina/metabolismoRESUMEN
Solid-pseudopapillary tumor (SPT) is an unusual pancreatic neoplasm that is characterized by a mixture of solid and cystic components and a fibrous capsule. Recently, the tumorigenesis of SPT has been reported to be associated with gene mutations of beta-catenin, which is a molecule participating in the Wnt signaling pathway. Reported herein is the case of a 53-year-old woman with SPT. The tumor, approximately 3 cm in diameter in the pancreas body, had a clear margin and central calcification but had neither a cystic component nor fibrous capsule. Several lines of pathological findings in the surgically resected specimen indicated SPT: (i) pseudopapillary proliferation of eosinophilic polygonal cells with oval nuclei; (ii) positive expression of several marker molecules indicating differentiation into acinar and endocrine cells; and (iii) zymogen granule-like structures in the cytoplasm on electron microscopy. Further, the tumor cells had intense nuclear accumulation of beta-catenin and an activating mutation, (34)Gly(GGA) to Arg(AGA), in exon 3 of the beta-catenin gene, as previously reported in most SPT. These findings suggest that association of the beta-catenin phenotype with development of the rare phenotype of SPT, a non-cystic and unencapsulated tumor, is unlikely.
Asunto(s)
Núcleo Celular/patología , Cistoadenoma Papilar/patología , Mutación , Neoplasias Pancreáticas/patología , beta Catenina/genética , Biomarcadores de Tumor/metabolismo , Cistoadenoma Papilar/genética , Cistoadenoma Papilar/metabolismo , Análisis Mutacional de ADN , Supervivencia sin Enfermedad , Femenino , Humanos , Persona de Mediana Edad , Pancreatectomía , Neoplasias Pancreáticas/genética , Neoplasias Pancreáticas/metabolismo , Vesículas Secretoras/ultraestructura , Análisis de Secuencia de ADN , beta Catenina/metabolismoRESUMEN
BACKGROUND/AIMS: Solid and pseudopapillary tumor of the pancreas is a benign and low malignant potential tumor. Prognosis is good after surgical resection but its malignant potential is usually defined after metastasis. We compared benign and malignant cases with clinicopathological, immunohistochemical and DNA flow cytometric studies. METHODOLOGY: From January 1991 to July 2004, seven patients were found to have solid and pseudopapillary tumor of the pancreas at Taipei Veterans General Hospital. The paraffin sections were reevaluated with hematoxylin & eosin stain, immunohistochemical stains, and DNA flow cytometric studies. RESULTS: It included 6 benign and one malignant case. The progesterone receptor, vimentin, neuron-specific enolase, and chromogranin A showed diffused positive stain in all cases. Estrogen receptor and P53 stain were negative in all 7 patients. Synaptophysin stain was negative in 6 no recurrence patients, but was positive only in the patient who suffered from recurrence. DNA flow cytometry showed diploid results in six non-malignant tumors. In the malignant patient, the tumor in the first operation showed diploid result, but tumors in second and third operations showed aneuploidy. CONCLUSIONS: Solid and pseudopapillary tumor of the pancreas should be considered as a potentially malignant disease in all patients and regular follow-up is mandatory.
Asunto(s)
Cistoadenoma Papilar , Neoplasias Pancreáticas , Adolescente , Adulto , Biomarcadores de Tumor/metabolismo , Niño , Cistoadenoma Papilar/genética , Cistoadenoma Papilar/metabolismo , Cistoadenoma Papilar/patología , Femenino , Humanos , Masculino , Neoplasias Pancreáticas/genética , Neoplasias Pancreáticas/metabolismo , Neoplasias Pancreáticas/patología , Fosfopiruvato Hidratasa/metabolismo , Ploidias , Receptores de Esteroides/metabolismo , Proteína p53 Supresora de Tumor/metabolismo , Vimentina/metabolismo , alfa 1-Antitripsina/metabolismoRESUMEN
Genes of the RAF family, which mediate cellular responses to growth signals, encode kinases that are regulated by RAS and participate in the RAS/RAF/MEK/ERK/MAP-kinase pathway. Activating mutations in BRAF have recently been identified in melanomas, colorectal cancers, and thyroid and ovarian tumours. In the present study, an extensive characterization of BRAF and KRAS mutations has been performed in 264 epithelial and non-epithelial ovarian neoplasms. The epithelial tumours ranged from adenomas and borderline neoplasms to invasive carcinomas including serous, mucinous, clear cell, and endometrioid lesions. It is shown that BRAF mutations in ovarian tumours occur exclusively in low-grade serous neoplasms (33 of 91, 36%); these included serous borderline tumours (typical and micropapillary variants), an invasive micropapillary carcinoma and a psammocarcinoma. KRAS mutations were identified in 26 of 91 (29.5%) low-grade serous tumours, 7 of 49 (12%) high-grade serous carcinomas, 2 of 6 mucinous adenomas, 22 of 28 mucinous borderline tumours, and 10 of 18 mucinous carcinomas. Of note, two serous borderline tumours were found to harbour both BRAF and KRAS mutations. The finding that at least 60% of serous borderline tumours harbour mutations in two members of the ERK-MAP-kinase pathway (BRAF 36%, KRAS 30%) compared with 12% of high-grade serous carcinomas (BRAF 0%, KRAS 12%) indicates that the majority of serous borderline tumours do not progress to serous carcinomas. Furthermore, no BRAF mutations were detected in the other 173 ovarian tumours in this study.
Asunto(s)
Cistadenoma Seroso/genética , Mutación , Neoplasias Ováricas/genética , Proteínas Proto-Oncogénicas c-raf/genética , Cistoadenoma Mucinoso/genética , Cistoadenoma Mucinoso/patología , Cistoadenoma Papilar/genética , Cistoadenoma Papilar/patología , Cistadenoma Seroso/patología , Femenino , Humanos , Neoplasias Ováricas/patología , Proteínas Proto-Oncogénicas/genética , Proteínas Proto-Oncogénicas B-raf , Proteínas Proto-Oncogénicas p21(ras) , Proteínas rasRESUMEN
Intraductal papillary mucinous tumors of the pancreas show a unique histologic feature in that the wide spectrum of intraductal epithelium is observed in the same pancreas. The aim of this study was to clarify whether or not the "clonal progression" relates to the development of this tumor. A total of 210 intraductal epithelium samples were microdissected from 23 resected specimens of intraductal papillary mucinous tumors of the pancreas, including nine carcinomas, five borderline tumors, and nine adenomas. After histologic grading (grades 1 to 4) of the individual epithelium, the K-ras point mutation and loss of heterozygosity in 9p21(p16) and 17p13(p53) were investigated. From the distribution of the K-ras point mutation of 210 microdissected specimens, an identical sequence of K-ras was demonstrated in the precursor lesions in most cases. K-ras mutation showed a single pattern, and the multiple or heterogeneous mutation pattern was not seen in this study. In the same ways, the distribution of loss of heterozygosity in 9p21(p16) and 17p13(p53) of 210 microdissected specimens was shown to be mostly clonal, without the presence of the genetic alterations. Such distributions of the identical genetic statuses in the precursor lesions are consistent with the presence of clonal progression during the development of this tumor.
Asunto(s)
Adenocarcinoma Mucinoso/genética , Adenocarcinoma Papilar/genética , Carcinoma Ductal Pancreático/genética , Cistoadenoma Mucinoso/genética , Cistoadenoma Papilar/genética , Genes ras/genética , Neoplasias Pancreáticas/genética , Adenocarcinoma Mucinoso/patología , Adenocarcinoma Papilar/patología , Carcinoma Ductal Pancreático/patología , Cromosomas Humanos Par 17 , Cromosomas Humanos Par 9 , Cistoadenoma Mucinoso/patología , Cistoadenoma Papilar/patología , Femenino , Humanos , Pérdida de Heterocigocidad , Masculino , Persona de Mediana Edad , Páncreas/patología , Conductos Pancreáticos/patología , Neoplasias Pancreáticas/patología , Mutación PuntualRESUMEN
K-ras point mutation, p53 over-expression, and telomerase activity have been proposed as molecular markers for clinical diagnosis of pancreatic carcinoma. To evaluate the clinical usefulness of these markers, we performed comparative analysis in 61 resected pancreatic samples including 15 intraductal papillary-mucinous tumours (IPMTs), 4 mucinous cystic tumours, 37 ductal adenocarcinomas, and five chronic pancreatitis samples. K-ras point mutation, telomerase activity, and p53 overexpression were analyzed using mutant allele specific amplification, the telomeric repeat amplification protocol, and immunohistochemical staining, respectively. In malignant tumours, K-ras mutation, telomerase activity, and p53 overexpression were detectable in 76, 91, and 46%, respectively, while in benign tumours, these alterations were detectable in 38, 0, and 0%, respectively. Among 15 IPMTs, K-ras mutation was detectable in 4 (80%) of 5 IPMT-adenomas, 4 (80%) of 5 IPMT-carcinomas and 2 (66%) of 3 papillary-mucinous carcinomas, which are invasive carcinomas derived from IPMTs. Telomerase activity was not detectable in IPMT-adenomas, but was detected in all 5 IPMT-carcinomas and 3 papillary-mucinous carcinomas. p53 overexpression was not detected in IPMTs, but was detected in 2 (66%) of 3 papillary-mucinous carcinomas, indicating that telomerase is likely to be activated concomitant with carcinogenesis. These results suggest that telomerase activity is the most useful as a differential diagnostic marker between malignant and benign pancreatic tumours.
Asunto(s)
Genes ras/genética , Neoplasias Pancreáticas/genética , Neoplasias Pancreáticas/metabolismo , Mutación Puntual , Telomerasa/metabolismo , Proteína p53 Supresora de Tumor/metabolismo , Adolescente , Adulto , Anciano , Biomarcadores de Tumor/análisis , Carcinoma Ductal Pancreático/genética , Carcinoma Ductal Pancreático/metabolismo , Carcinoma Ductal Pancreático/patología , Carcinoma Papilar/genética , Carcinoma Papilar/metabolismo , Carcinoma Papilar/patología , Cistoadenoma Papilar/genética , Cistoadenoma Papilar/metabolismo , Cistoadenoma Papilar/patología , Femenino , Humanos , Técnicas para Inmunoenzimas , Masculino , Persona de Mediana Edad , Neoplasias Quísticas, Mucinosas y Serosas/genética , Neoplasias Quísticas, Mucinosas y Serosas/metabolismo , Neoplasias Quísticas, Mucinosas y Serosas/patología , Neoplasias Pancreáticas/patología , Pancreatitis/genética , Pancreatitis/metabolismo , Pancreatitis/patología , Pronóstico , Regulación hacia ArribaRESUMEN
The role of FSHR expression in ovarian cancer development is not clear. We examined quantitative expression of FSHR in different types of OET, presumed precursor lesions and peritoneal implants and further discussed FSH as a key growth-promotion factor for the process of ovarian epithelial tumorigenesis. Thirty-five primary OET specimens, including 5 serous cystadenomas, 4 papillary serous cystadenomas, 9 SBTs and 17 serous carcinomas, were examined for quantitative FSHR expression. Ten paired samples (3 benign cystadenomas, 5 SBTs and 2 carcinomas) were obtained from several morphologically different areas, including benign-looking, borderline and cancerous areas in the same OETs, and from the remaining ovarian tissue and contralateral ovaries. Competitive RT-PCR was performed to measure the quantitative expression of FSHR in each tissue sample. FSHR expression levels were compared among nonpaired samples and within paired samples. We found that OSE had the lowest FSHR expression, whereas antral follicles had the highest level. Within benign OETs, papillary serous cystadenomas have 4.9-fold higher FSHR levels than nonpapillary serous cystadenomas. SBTs had the highest level of FSHR expression, which was 12.8-fold, 2.7-fold and 2.4-fold higher than that of serous cystadenomas, papillary serous cystadenomas and grade 1 carcinomas, respectively. A similarly high level of FSHR mRNA was found in peritoneal implants, which were associated with SBTs. FSHR levels among serous carcinomas decreased with an increase in carcinoma grade. Grade 3 carcinomas had the lowest FSHR level, which was similar to that of serous cystadenomas, while grade 1 carcinomas had 6.5-fold higher FSHR levels than those in serous cystadenomas. Our results suggest that not only serum FSH but also FSHR in ovarian epithelium may play important roles in ovarian OET development. Both the receptor and ligand may act in a synergistic way to promote tumor growth. The observation that high FSHR levels are present in peritoneal implants suggests that FSH may also play a similar role in the development of peritoneal serous tumors. From this perspective, circulating FSH may be considered a driving force in the field effect theory for the development of both ovarian neoplasms and their associated peritoneal implants. However, the exact role of FSH and/or FSHR in the development of epithelial tumors arising in both the ovary and peritoneum needs further investigation.
Asunto(s)
Cistadenoma Seroso/metabolismo , Conductos Paramesonéfricos/patología , Neoplasias Ováricas/metabolismo , ARN Mensajero/metabolismo , Receptores de HFE/metabolismo , Adulto , Anciano , Estudios de Casos y Controles , Cistoadenoma/genética , Cistoadenoma/metabolismo , Cistoadenoma/patología , Cistoadenoma Papilar/genética , Cistoadenoma Papilar/metabolismo , Cistoadenoma Papilar/patología , Cistadenoma Seroso/genética , Cistadenoma Seroso/patología , Cartilla de ADN/química , Epitelio/metabolismo , Femenino , Humanos , Persona de Mediana Edad , Neoplasias Ováricas/genética , Neoplasias Ováricas/patología , Ovario/metabolismo , ARN Mensajero/genética , Receptores de HFE/genética , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
Solid-pseudopapillary tumors (SPTs) are unusual pancreatic neoplasms of low malignant potential that most frequently affect young women. Genetic events contributing to the development of SPTs are unknown. Whereas the more common ductal adenocarcinomas of the pancreas essentially never harbor beta-catenin or APC gene mutations, we have recently identified alterations of the APC/beta-catenin pathway in other nonductal pancreatic neoplasms including pancreatoblastomas and acinar cell carcinomas. We analyzed a series of 20 SPTs for somatic alterations of the APC/beta-catenin pathway using immunohistochemistry for beta-catenin protein accumulation, direct DNA sequencing of beta-catenin exon 3, and direct DNA sequencing of the mutation cluster region in exon 15 of the APC gene in those SPTs that did not harbor beta-catenin mutations. Immunohistochemical labeling for cyclin D1 was performed to evaluate the overexpression of this cell-cycle protein as one of the putative downstream effectors of beta-catenin dysregulation. In addition, we analyzed the SPTs for genetic alterations commonly found in pancreatic ductal adenocarcinomas, including mutations in the K-ras oncogene and p53 and DPC4 tumor suppressor genes, using direct DNA sequencing of K-ras and immunostaining for p53 and Dpc4. Almost all SPTs harbored alterations in the APC/beta-catenin pathway. Nuclear accumulation of beta-catenin protein was present in 95% (19 of 20), and activating beta-catenin oncogene mutations were identified in 90% (18 of 20) of the SPTs. Seventy-four percent (14 of 19) showed overexpression of cyclin D1, ranging from 10 to 70% of tumor nuclei. In contrast, no K-ras mutations were present in any of the 20 SPTs, and Dpc4 expression was intact in all 16 SPTs for which immunohistochemical labeling was successful. Overexpression of p53 was limited to only 3 of 19 (15.8%) SPTs. These results emphasize the two distinct, divergent genetic pathways of neoplastic progression in pancreatic ductal and nonductal neoplasms.
Asunto(s)
Carcinoma Ductal de Mama/genética , Cistoadenoma Papilar/genética , Proteínas del Citoesqueleto/genética , Mutación , Neoplasias Pancreáticas/genética , Transactivadores , Adolescente , Adulto , Anciano , Secuencia de Bases/genética , Cistoadenoma Papilar/patología , Femenino , Expresión Génica , Genes p53 , Genes ras , Humanos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Mutación/fisiología , Neoplasias Pancreáticas/patología , beta CateninaAsunto(s)
Deleción Cromosómica , Cromosomas Humanos Par 6/genética , Cistoadenoma Papilar/genética , ADN de Neoplasias/análisis , Interpretación Estadística de Datos , Neoplasias Peritoneales/genética , Cistoadenoma Papilar/patología , Femenino , Humanos , Pérdida de Heterocigocidad , Neoplasias Ováricas/genética , Neoplasias Ováricas/patología , Neoplasias Peritoneales/patologíaRESUMEN
The tumour suppressor gene CDKN2A, located on chromosome 9p21, encodes the cell cycle regulatory protein p16. Inactivation of the CDKN2A gene could lead to uncontrolled cell growth. In order to determine the role of CDKN2A in the development of sporadic ovarian cancer, loss of heterozygosity at 9p21-22, homozygous deletion, mutation and methylation status of the CDKN2A gene as well as CDKN2A expression were examined in a panel of serous papillary ovarian cancer. The frequency of loss of heterozygosity (LOH) for one or more informative markers at 9p21-22 was 65% (15/23). The most common deleted region was located between interferon (IFN)-alpha and D9S171. Homozygous deletions and mutations of the CDKN2A gene were not found. There was no evidence of methylation in exon 1, but methylation in exon 2 of CDKN2A gene was found in 26% (6/23). Absence of CDKN2A gene expression was shown in 27% (6/22) at mRNA level and 21% (4/19) at protein level. These data suggest that the CDKN2A gene is involved in the tumorigenesis of ovarian cancer, but the mechanisms of CDKN2A gene inactivation in serous papillary ovarian cancer remains unclear.
Asunto(s)
Cromosomas Humanos Par 9 , Inhibidor p16 de la Quinasa Dependiente de Ciclina/genética , Cistoadenoma Papilar/genética , Eliminación de Gen , Genes p16 , Pérdida de Heterocigocidad , Neoplasias Ováricas/genética , Mapeo Cromosómico , Cistoadenoma Papilar/cirugía , Metilación de ADN , Cartilla de ADN , Femenino , Marcadores Genéticos , Homocigoto , Humanos , Neoplasias Ováricas/cirugía , Reacción en Cadena de la Polimerasa , Biosíntesis de Proteínas , ARN Mensajero/análisis , Transcripción GenéticaRESUMEN
Five years after the identification of the von Hippel-Lindau (VHL) gene, physicians, scientists and concerned VHL family members met to review the current state of knowledge on the diagnosis and treatment of VHL and to summarize the latest information on the biochemistry of the VHL protein (pVHL). The NIH and University of Pennsylvania groups reported the detection of germ-line mutations in 100% (93 of 93) of VHL families studied. Several studies determined the frequency of VHL germ-line mutations in individuals with a single manifestation of VHL without a family history of VHL. National groups to improve the diagnosis and treatment of individuals with VHL disease have been established in Great Britain, Denmark, France, Holland, Italy, Japan, Poland, and the United States. Evidence for the existence of genes that modify the expression of VHL was presented. The VHL protein appears to have several distinct functions: (a) down-regulation of hypoxia-inducible mRNAs; (b) proper assembly of the extracellular fibronectin matrix; (c) regulation of exit from the cell cycle; and (d) regulation of expression of carbonic anhydrases 9 and 12.